Trial Profile
A 24 week, double blind, randomized study to investigate the effect of 500 microg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstructive pulmonary disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms HERO
- 04 May 2012 Additional lead trial investigator (D. Bredenbroker) identified as reported by ClinicalTrials.gov.
- 04 May 2012 Company added to the associations field as reported by ClinicalTrials.gov record.
- 25 Jan 2012 Additional trial identifier (NCT00108823) identified as reported by ClinicalTrials.gov.